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above baseline (Figure 1). Surgery to remove osteochondral fragments at
week 16 did not result in any biomarker changes 1 week after surgery.
By week 18 there was a signiﬁcant increase in CTX II (P = 0.043) in the
saline control horses from week 17, and a trend towards increasing
concentrations of C2C (P = 0.11), C12C (P = 0.06), and CPII (P = 0.051).
By week 20, biomarker concentrations of CPII, C12C and CTX II had
decreased to week 16 pre-surgical concentrations in the saline control
horses. C2C however had signiﬁcantly increased concentrations from
week 17 and 18. One week (week 18) after injection with TA, C2C,
C12C, and CPII concentrations were all signiﬁcantly increased compared
to saline controls. In contrast, CTX II was signiﬁcantly lower than saline
controls (Figure 1). By 3 weeks (week 20) after TA injection, CPII and C12C
concentrations were no different than saline controls or week 16 pre-
surgical values. However, C2C concentrations continued to increase and
CTX II concentrations were still signiﬁcantly lower than saline controls.
Conclusions: Arthroscopic surgery to remove osteochondral fragments
did not affect collagen biomarkers by 1 week after surgery. By 2 weeks
after surgery (1 week after saline injection), overall metabolism increased
(CPII, C12C, and CTX II), which may be a delayed effect of surgery or in
response to saline injection. Intra-articular corticosteroid injection post-
operatively produced different responses in each biomarker, with both
catabolic and anabolic effects. After 1 week, CPII, C12C, and C2C were
increased, but by 3 weeks after administration, it appeared that the
joint was starting to become more catabolic with CPII concentrations
decreasing and C2C concentrations increasing. This suggests that TA
administration does not down regulate all collagenase activity in the
joint. TA dramatically decreased CTX II concentrations similarly to
ibuprofen which may be due to cathepsin K inactivation. Further
biomarker studies are needed to determine the affect of surgery and
intra-articular treatment on the joint.
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VISCOELASTIC PROPERTIES AND MOLECULAR WEIGHT OF HYLAN
G-F 20 COMPARED WITH OTHER COMMERCIAL HYALURONAN BASED
VISCOSUPPLEMENTS
L-P. Yu, H. Yang, E. Voschin, E. Skrabut. Genzyme Corp., Framingham, MA,
USA
Purpose: Visosupplementation with hyaluronan (HA)-based products
has been used clinically to provide relief of pain due to osteoarthritis.
This study compared the rheological properties and molecular weight
(MW) of hylan G-F 20 (Synvisc® or Synvisc-One®) to several commercially
available HA containing viscosupplements (VS). The percent elasticity
was evaluated as a function of molecular weight. Analgesic properties of
VS products are believed to be at least partially a function of elasticity
within the joint space.
Methods: Viscoelasticity was studied using a controlled stress rheometer
in the frequency range of 0.04–7Hz at 25°C. The percent elasticity
was calculated as a function of the elastic and viscous moduli. The
viscosity at shear rate 1 sec−1 (h(1)) was also determined. Size exclusion
chromatography (SEC) with multi-angle laser light scattering (MALLS)
was used to provide a direct determination of average molecular weight
(MW) and concentration of soluble HA. Each VS was diluted and
centrifuged to separate the gel phase (if any), then the supernatant
was analyzed by SEC/MALLS.
Results: The viscoelastic properties, percent elasticity, gel/ﬂuid
concentrations, and soluble HA MW for the VS products are listed in
the table below. Values for human synovial ﬂuid, obtained from the
literature, are also listed. Hylan G-F 20 shows much higher viscoelasticity
as demonstrated by its low crossover frequency (<0.01Hz), low phase
angle (<25°), and much higher shear viscosity and percent elasticity. Of
the products tested, Synvisc also showed the highest percent elasticity,
being similar to healthy young synovial ﬂuid. All products, except
Monovisc™, have similar total HA concentration; however, hylan G-F
20 had the highest soluble (ﬂuid) HA average MW (5.5 million) whereas
the other products had a MW of 1.6 million or less. The effect of HA MW
on product’s elasticity has been evaluated. As shown in the ﬁgure below,
the percent elasticity has a strong correlation with MW, and is less
affected by the HA concentration. Thus Monovisc, containing twice the
concentration of soluble HA, showed only 47% elasticity due to its low HA
MW. On the other hand, normal young synovial ﬂuid, which contained
less than 5mg/ml HA, still showed 72% elasticity. These results suggest
that when rheology, MW and concentration are considered together,
hylan G-F 20 has aggregate physicochemical properties most similar to
healthy young synovial ﬂuid.
Conclusion: The molecular weight of hylan G-F 20 is substantially
higher than the other viscosupplements tested. Low molecular weight
viscosupplements demonstrated a percent elasticity less than half of
that observed for hylan G-F 20. When injected intra-acticularly, high
percent elasticity and high viscosity are critical for shock absorption and
lubrication in the joint. The inclusion of high MW HA in Synvisc resulted
in viscoelastic properties more similar to healthy young synovial ﬂuid.
Figure: Effect of HA MW on % elasticity.
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Aim: To detect the inter-observer variance of arthroscopic cartilage
grading by subjective judgment using the ICRS (International Cartilage
Repair Society) score and by objective measurement using NIRS (near-
infrared spectroscopy).
It was hypothesized that objective measurement of cartilage lesions by
NIRS yielded more valid results than routine grading utilizing the ICRS
score.
Methods: Fifteen patients who had undergone arthroscopic knee
operations were evaluated by four experienced arthroscopists. The
cartilage lesions within the medial knee compartment were estimated
observer-independently by using the ICRS grade and by measurements
with a special arthroscopic NIRS-probe.
Results: The ICRS grading had a poor inter-observer agreement, with a
mean Fleiss-Kappa-Index of K =0.173. Only in a total of six from sixty
(10.0%) judged cartilage areas did all four surgeons grade the cartilage
areas with the same result. In 17 areas (28.3%), the surgeons had a
variance of two or more grades. In the residuary cases, the surgeons
varied within one grade.
The objective NIRS-obtained measurements of cartilage resulted in
a signiﬁcant correlation within the observers of R =0.885±0.036;
p < 0.001.
Conclusion: Our results of inter-observer evaluation in real-time
arthroscopic cartilage grading suggest that this subjective grading is not
satisfactory. This study emphasizes the need for objective measurement
techniques for an evident arthroscopic cartilage grading. Near-infrared
spectroscopy (NIRS) has a good inter-observer correlation. Thus, this
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method could be developed in the future as a precise method of
measuring cartilage lesions.
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ADDITION OF SORBITOL TO HYALURONIC ACID MAY REDUCE THE
ONSET OF ACTION OF VISCOSUPPLEMENTATION IN PATIENTS WITH
SYMPTOMATIC KNEE OSTEOARTHRITIS
T. Conrozier1, Y. Mornand2, O. Benoit3, E. Vignon1. 1Ctr. Hosp.ier Lyon
Sud, Pierre Be´nite, France; 2Ctr. de Rhumatologie Lyon Presqu’ile, Lyon,
France; 3Anteis, Plan les Ouates, Switzerland
Purpose: Viscosupplementation by intraarticular injections of hyaluronic
acid (HA) reduces pain and improves function in patients with knee
osteoarthritis (KOA) but the improvement is delayed and occurs usually
6 to 8 weeks after the injections.
ANTI-OX-VS is an innovative viscosupplement made of a high
concentration (20mg/ml) of a 2mDa hyaluronic acid (HA) from non
animal origin, combined with a high concentration of a free radical
scavenger, the sorbitol (40mg/ml). The high afﬁnity between HA and
sorbitol, stabilizes the complex through a very dense network of
hydrogen bonds. The high ability of sorbitol to scavenge and neutralize
reactive oxygen specie (ROS) has been demonstrated to delay the
degradation of the gel due to ROS. We hypothesise that the antioxidant
effect of sorbitol may also play a role to reduce the time to onset of
analgesia.
Objectives: To evaluate the short term pain-relief effect of ANTI-OX-VS
in patients suffering from KOA.
Patients and Methods: Thirteen-week (W) prospective open pilot study.
30 patients suffering from symptomatic KOA (tibiofemoral and/or
patellofemoral, grade 2 to 4) were treated by intra-articular injections
of ANTI-OX-VS. Each patient received 3 intra-articular injections of 2mL
one week apart. Pain and function using the WOMAC scale, walking
pain (WP), patient and physician global assessment (GA) using a 5 point
Likert scale, and percentage of improvement since the ﬁrst injection
were obtained at baseline, W1, W2 and end point (W13). Between the
third injection and W13 patients were asked to complete once a week a
self evaluation questionnaire including WP, WOMAC A, patient GA and
adverse events (AEs).
Primary criteria was the variation of WP between ﬁrst injection and
W3. Secondary criteria: were: Variation of WP, WOMAC A, PGA between
baseline and W1, W2, W3, W8, W13. Variation of WOMAC between
baseline and W13. Percentage of improvement between baseline and
W1, W2, W13.
Results: At baseline mean WP was 2.1 and WOMAC A 8.3. WP
dramatically decreased 1 week after the ﬁrst injection (1.6, p < 0.0003).
At W3 mean WP was 1.5 (p < 0.0003) and decreased again to 1.0 at W13
(p < 0.0001). The mean decrease of WOMAC A at W1, W2, W8 and W13
was −2.1, −2, −2 and −3.9 respectively.
Figure: Mean walking pain assessment by the patient.
Conclusions: This exploratory study suggests a quick and strong pain
relief occurring immediately after the ﬁrst injection of ANTI-OX-
VS, followed by a continuous improvement until the end of follow-
up. Improvement was achieved much faster than that obtained with
other viscosupplements probably because of the presence of high
concentrations of sorbitol through its antioxidant activity. These data
support the need for a large-scale, prospective clinical trial comparing the
safety and long term efﬁcacy of ANTI-OX-VS to regular viscosupplement.
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EVALUATION OF THE EFFECT OF ADDING CORTICOSTEROID TO
VISCOSUPPLEMENTATION: A PROSPECTIVE AND RANDOMIZED STUDY
G.C. Campos. IOT – FMUSP, Campinas, Brazil
Purpose: Clinical studies in the treatment of knee osteoarthritis
have demonstrated that intraarticular injection of hyaluronic acid
provides good results only within 4 weeks after inﬁltration, while
the intraarticular injection of corticosteroids provides good immediate
results, which, however, are lost between 2 and 4 weeks. It is also
known that corticosteroid injection is more effective for knee pain and
function from baseline until the fourth week than viscosupplementation,
time when the results get equivalent for both procedures. After that, up
to 6 months, the injection of hialuronic acid shows better results. The
aim of this study is to assess if we can improve the initial results of
viscosupplementation by the addition of corticosteroids to the procedure,
while keeping the long-term results;
Methods: We evaluated 90 patients with osteoarthritis of the knee,
divided into two groups. Patients in group 1 received knee inﬁltration
of 6ml of Hylan alone. Patients in group 2 received knee inﬁltration of
6ml of Hylan and 1ml (20mg) of hexacetonide Triamcinolone.
We applied the visual analogic scale of pain (VAS) and the
functional questionnaires WOMAC and Lequesne. The questionnaires
were answered before inﬁltration (week zero) and with one, four, twelve
and twenty-four weeks after the puncture (weeks 1, 4, 12 and 24)
Results: The mean age of patients was 61.89 yo. Most were female
(75.5%). The average BMI of patients was 29.75. The radiological
classiﬁcation (Kellgreen and Lawrence) was on average 2.71. Preoperative
scores: WOMAC = 52.47 (SD=17.74); VAS = 69.29 (SD=21.79); Lequesne
= 13.49 (SD=4.24). The groups were statistically analyzed and found to
be parametric.
Week 1:
Group 1 did not show a statistically signiﬁcant improvement compared to
baseline for WOMAC. VAS showed improvement of 13.82% (p =0.007)
and Lequesne improvement of 8.2% (p =0.02)
Group 2 showed improvement in WOMAC (39.02%), VAS (44.08%) and
Lequesne (21.14%), all with a p < 0.01.
Week 4:
Group 1 showed improvement from baseline of 9.3% in WOMAC, 15.04%
in VAS and 13.50% in Lequesne, all p < 0.05;
Group 2 was increased to 43.0% of improvement in Womac, 48.6% in the
VAS and 27.4% in Lequesne, all p < 0.01.
Group 2 is superior to group 1 in all scores at weeks 1 and 4, p < 0.01.
Aroud 33% of the patients reportes adverse effects such as disconfort
(10%) joint effusion (7%) and some degree of pain (22%). The pain lasted
69% longer in group 1 with p < 0.05 (3.26 days against 1.92 days)
Conclusion: We concluded that the addition of 1ml of triancinolone to
the viscosupplementation brings great improvement to the initial results
of the procedure.
